Core Viewpoint - *ST Jingfeng has successfully completed its restructuring process, leading to a significant recovery in its stock price, which has been labeled as the "limit-up king" of A-shares in 2024 [4][10]. Group 1: Restructuring Process - On March 17, *ST Jingfeng announced its application to revoke the delisting risk warning after the court approved the completion of its restructuring plan [5][9]. - The restructuring process began with a pre-restructuring phase initiated by the Changde Intermediate Court on July 2, 2024, and involved the selection of Shiyao Holdings as the lead investor [15][19]. - The restructuring agreement was signed on April 29, 2025, and the plan was officially approved by the court on February 3, 2026, marking the end of the restructuring process [6][19]. Group 2: Stock Performance - Following the announcement of the restructuring completion, *ST Jingfeng's stock price surged, reaching a limit-up of 6.14 yuan per share on March 19 [8][10]. - The stock experienced a total of seven limit-up days from March 5 to March 18, reflecting strong market interest [10]. Group 3: Financial Performance - For the fiscal year 2025, *ST Jingfeng projected revenues between 360 million to 420 million yuan, with a net loss forecasted between 60 million to 90 million yuan, indicating a return to losses after a brief profit in 2024 [21]. - The company attributed the previous year's profit to a debt waiver of 110 million yuan, which significantly impacted its financial results [21]. Group 4: Future Business Strategy - The restructuring plan outlines a focus on traditional Chinese medicine and biopharmaceuticals, with an emphasis on enhancing the product structure and phasing out non-competitive products [22]. - The plan includes systematic research on the anti-tumor product Lanjing, aiming to improve quality standards and expand its applications in cancer treatment [22].